Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Ganli Pharmaceutical: Sitagliptin and Metformin Tablets (II) Approved, Cumulative Investment of 9.29 Million Yuan
Recently, Gan & Lee Pharmaceutical issued an announcement stating that its wholly owned subsidiary received a product registration approval letter from the National Medical Products Administration for Sitagliptin Metformin Hydrochloride Tablets (II). The acceptance number is CYHS2403373, and the drug registration certificate number is 2026S00914.
The drug is a fixed-dose combination product and is indicated for patients with type 2 diabetes whose blood glucose control is not satisfactory with metformin monotherapy. Sitagliptin Metformin Hydrochloride Tablets (II) were approved for marketing by the European Medicines Agency in 2008, granted marketing authorization in China in 2012, and were included in the National Reimbursement Drug List in 2019.
The announcement mentioned that Gan & Lee Pharmaceutical has cumulatively invested RMB 9.29 million in R&D expenses for this project. This approval will further enrich the company’s product layout in endocrinology treatment.
(Gan & Lee Pharmaceutical announcement)
(Editor: Yang Yan, Lin Chen)
Keywords: